Detalles de la búsqueda
1.
Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
J Pharmacol Exp Ther
; 385(2): 106-116, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36849412
2.
Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition.
J Pharmacol Exp Ther
; 384(3): 331-342, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36241203
3.
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
J Pharmacol Exp Ther
; 352(3): 579-89, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25576074
4.
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.
Cancer Res Commun
; 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727236
5.
Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.
J Med Chem
; 66(14): 9376-9400, 2023 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37450324
6.
SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma.
bioRxiv
; 2023 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38106234
7.
Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance.
bioRxiv
; 2023 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36747713
8.
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
Cancer Discov
; 12(4): 924-937, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35046095
9.
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
J Thorac Oncol
; 16(8): 1321-1332, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33971321
10.
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
J Med Chem
; 64(10): 6569-6580, 2021 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33719426
11.
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Cancer Discov
; 11(1): 142-157, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32816843
12.
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
Mol Cancer Ther
; 19(4): 1059-1069, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32054790
13.
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Mol Cancer Ther
; 19(4): 1018-1030, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32024684
14.
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver.
J Pharmacol Exp Ther
; 325(1): 284-92, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18171905
15.
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Oncogene
; 37(20): 2687-2701, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29491412
16.
An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor.
Cancer Chemother Pharmacol
; 79(3): 545-558, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28243682
17.
The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.
Mol Cancer Ther
; 16(10): 2223-2233, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28729397
18.
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques.
Cancer Chemother Pharmacol
; 77(6): 1303-14, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27160688
19.
Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
J Med Chem
; 59(10): 4462-75, 2016 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-26914985
20.
BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.
Mol Cancer Ther
; 14(12): 2762-72, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26438154